MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of Directors has authorized a share repurchase program (the “Repurchase Program”) for up to $20 million of the Company’s outstanding shares of common stock (“Common Stock”).
Related Questions
How will the $20 million share repurchase affect Incannex’s cash reserves and liquidity?
What is the expected impact of the buyback on the stock’s price and earnings per share (EPS) in the short term?
When is the repurchase program scheduled to commence and what is the anticipated execution timeline?